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Slow reconstitution of T cell immunity remains a critical issue after umbilical cord blood (CB) transplantation.
Although this may be a consequence of the low cell dose, it may also reﬂect the propensity of naïve T cells,
which predominate in CB, to undergo apoptotic cell death. Exogenous interleukin 7 (IL-7) can prevent
apoptosis of naïve T cells, but at high concentrations, IL-7 may also expand alloreactive T cells, thereby
aggravating the risk of graft-versus-host disease. We evaluated the survival of CB T cells from 34 healthy full-
term pregnancies, and we found wide interdonor variation, from 17.4% to 79.7%, of CB T cells that were still
alive after being rested for 4 days in culture medium without cytokine supplementation. The viability of CB T
cells was negatively correlated to infant birth weight (Spearman’s r ¼ .376; P ¼ .031) and positively correlated
to venous CB pH (r ¼ .397; P ¼ .027); both associations were conﬁrmed by multivariate analysis (P ¼ .023 and
P ¼ .005, respectively). A low supplemental concentration (100 pg/mL) of recombinant human IL-7 was
sufﬁcient to maintain the viability of cryopreserved/thawed CB T cells, with most (>80%) cells remaining in a
quiescent state and without signiﬁcant changes in their CD4/CD8 ratio and the proportion of CD4þ CD31þ
PTK7þ recent thymic emigrants. IL-7 at 100 pg/mL did not lead to any signiﬁcant enhancement of the
alloreactive response of CB T cells, as evaluated by proliferation rates (thymidine incorporation and carbox-
yﬂuorescein diacetate succinimidyl ester dilution) and interferon-gamma production (ELISPOT). This effective
concentration of IL-7 is far lower than that obtained in vivo after pharmacological administration of the
cytokine. This study suggests that administration of lower doses of recombinant human IL-7 than used in
previous clinical trials may be sufﬁcient to sustain the viability of infused CB T cells and, thus, help to
accelerate naïve T cell reconstitution without potentiating their alloreactivity.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Slow reconstitution of T cell adaptive immunity and graft-
versus-host disease (GVHD) remain critical issues after
allogeneic hematopoietic stem cell transplantation.
Compared with conventional allografts from matched
unrelated donors, umbilical cord blood (CB) transplantation
may allow a greater degree of HLA disparities, but it often
leads to a more gradual immune reconstitution [1,2]. T cellsdgments on page 630.
quests: Prof. Myriam Labalette, MD, PhD,
e HLA, Centre de Biologie - Pathologie du
eur Jules LECLERCQ, 59037 LILLE CEDEX,
te@chru-lille.fr (M. Labalette).
14.11.678
ty for Blood and Marrow Transplantation.brought by CB grafts are almost exclusively naïve, include a
high proportion of functionally immature recent thymic
emigrants (RTEs), and are particularly prone to apoptosis
[3,4]. Together with a relatively low graft nucleated cell dose,
infusion of apoptosis-prone T cells would likely lead to their
shortened survival in the host, which suggests that the long-
lasting immunodeﬁciency after CB transplantation may be
due, in part, to the rapid disappearance of most of the infused
T cells.
Interleukin-7 (IL-7) is a major homeostatic cytokine
essential to naïve T cell survival as well as homeostatic
expansion of T cells [5], which is the primary process
involved in the ﬁrst months of immune reconstitution and
remains the main contributor to reconstitution in adult
recipients, particularly the older recipients. Peak circulating
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tained after administration of recombinant human IL-7 to
improve T cell recovery in lymphopenic patients [6,7]. Such a
high concentration is reportedly effective at preventing
resting CB T cells from death in culture [8,9] and may induce
a variable capacity to produce interferon-g and other cyto-
kines upon in vitro stimulation [10]. High IL-7 concentrations
may expand alloreactive and autoreactive T cells [11], which
may induce and/or potentiate GVHD, as indicated both by
preclinical models [12] and by the association found in some
clinical studies between high systemic IL-7 levels and acute
GVHD rates [13,14]. With this in mind, we sought to inves-
tigate whether lower IL-7 concentrations could sufﬁce to
maintain CB T cell viability without exaggerating their acti-
vation and alloreactivity. We observed a broad individual
variation in survival of CB T cells from term placentas and
demonstrated that culture of cryopreserved/thawed CB T
cells in the presence of .1 ng/mL of recombinant human IL-7
could be sufﬁcient to sustain T cell viability without boosting
the allo-immune response.
MATERIALS AND METHODS
CB and Adult Peripheral Blood Cell Isolation
The CB and adult peripheral blood samples were collected under the
ethical approval of the Lille University Hospital Human Research committee
(DC 2011-1288). Umbilical CB (50 to 100 mL) was obtained from 34 healthy
full-term neonates (38 to 42 weeks of gestation) immediately after un-
complicated vaginal delivery of a low-risk pregnancy and single gestation,
using methods that met the standards for the collection for CB banking and
after signed informed consent from the mothers. Birth characteristics were
collected (Table 1). CB plasma samples were analyzed using a high-
sensitivity ELISA (IL-7 highly-sensitive Quantikine ELISA kits, R&D
systems, Minneapolis, MN). Mononuclear cells were isolated by standard
Ficoll-paque (GE, Uppsala, Sweden) density-gradient centrifugationwithin 3
hours after CB collection, washed in phosphate-buffered saline, and then
either used directly or suspended in freezingmedium (Recovery Cell Culture
Freezing Medium, Gibco, Invitrogen, Oslo, Norway) containing 10% DMSO
and cryopreserved in liquid nitrogen. Cryopreserved cells were kept frozen
for 4 months on average (range, 15 days to 1 year) and then thawed quickly
in a 37C water bath and washed immediately before use in RPMI medium
containing 1 mM of ethylenediamine tetraacetic acid. T cells were isolated
from fresh or cryopreserved/thawed CB mononuclear cells by negative
immunomagnetic selection (EasySep Human T cell Enrichment kit, StemCell
Technologies, Vancouver, Canada), yielding >95% CD3þ cells by ﬂow
cytometry. Mononuclear cells and T cells were similarly puriﬁed from pe-
ripheral blood from consenting healthy adults andwere used as controls and
to isolate allogeneic stimulators by negative immunomagnetic selection
(EasySep Monocyte Enrichment kit, StemCell Technologies).
Immunophenotypic Analysis of CB T Cells
CB T cell populations were analyzed before and after culture. All
directly conjugated antibodies and isotype controls were from BeckmanTable 1
Analysis of the Association between Clinical Characteristics of CB Donors and the Via
Exogenous Cytokine Supplementation
Characteristic Median (range) Co
Sp
Gestational age at partition, wk 40 (37.8-42) .0
Infant birth weight, kg 3.49 (1.98-4.43) .3
Infant gender (M/F)z 12/22
Apgar score 10 (2-10) .0
Venous CB pH 7.37 (7.14-7.48) .3
CB plasma IL-7 level (pg/mL)x 0 (0-6.67) .3
RTE: CD4þ CD31þ PTK7þ cells (%) 76.6 (61-85) .5
NS indicates not signiﬁcant; M, male; F, female.
* Cryopreserved CB T cells were thawed and maintained in complete culture
(3)-positive and propidium iodideenegative) were enumerated after four days.
y Multivariate analysis by using the general linear model. Only values achieving
z Mann-Whitney U test was used to test for differences by gender.
x Normal values in healthy adults: median 2 pg/mL (range, .6 to 7.7 pg/mL) [15]Coulter (Fullerton, CA), with the exception of the monoclonal antibody to
CD127 (IL-7 receptor alpha chain) from eBioscience (Paris, France) and the
monoclonal antibody to protein tyrosine kinase-7 (PTK7) from Miltenyi
Biotech (Bergisch Gladbach, Germany). Live-gated lymphocytes were
simultaneously acquired with internal bead standards (Flow-Count ﬂuo-
rospheres, Beckman Coulter) by multiparameter ﬂow cytometry (Navios,
Beckman Coulter) to obtain absolute cell counts. Expression of CD127 and
CD31 was evaluated by determining the proportion of cells with positive
staining and their mean ﬂuorescence intensity. Cell viability was assessed
by ﬂow cytometric scatter analysis and colabeling with 50 nM 3,3’-
dihexyloxacarbocyanine iodide (DiOC6(3); Invitrogen, Carlsbad, CA) and
propidium iodide (Sigma-Aldrich, St. Louis, MO) as instructed by the
manufacturers. To determine whether cultured cells had undergone
cellular proliferation, CB T cells (1  106/mL) were ﬁrst pulsed with car-
boxyﬂuorescein diacetate succinimidyl ester (CFSE) (5 mM; Invitrogen),
then quenched with 50% fetal calf serum, and washed 2 times in
phosphate-buffered saline before initiation of cultures. The population of
cells that have undergone successive cellular divisions was characterized
by serial halving of the ﬂuorescence intensity.
Unstimulated CB T Cell Cultures
Unstimulated CB T cell cultures were established at 1  105/well in
round bottom 96-well plates in complete RPMI medium containing 2 mM L-
glutamate, 2 mM pyruvate, 10% heat-inactivated human AB serum (J. Boy
Institute, Reims, France) and antibiotics. Depending on the experiments,
cultures of CB T cells were either matched with cultures of adult T cells or
run in parallel in the presence or absence of recombinant human IL-7 (R&D
Systems) at an initial concentration of 25 to 1000 pg/mL, with additional IL-
7 added daily thereafter at the same concentration. After different times of
culture at 37C and 5% CO2, the number of viable cells and cellular prolif-
eration were determined as described above.
One-way Mixed Lymphocyte Reactions
Mixed lymphocyte reactions (MLR) were established in triplicate us-
ing unlabeled or CFSE-labeled CB T cells (1 105 cells/well) as responders.
Allogeneic monocytes from adults with 4 to 6/6 HLA disparities with the
responders, including at least 1 HLA-DR disparity, were chosen as stim-
ulators (1  104 cells/well). HLA typing for A, B, and DR loci was done in
our tissue typing laboratory. Proliferation was assessed after 5 days by
CFSE dye dilution or by pulsing with methyl 3H-thymidine (18.5 kBq/well;
PerkinElmer, Waltham, MA) for the ﬁnal 18 hours of the culture and
microbeta scintillation counting (TopCount Microplate Scintillation
Counter, PerkinElmer). Interferon-g enzyme-linked immunosorbent spot
assays (IFN-g ELISPOT) were performed with 2  105 viable cells har-
vested after 7 days from the triplicate MLR cultures and recultured for an
additional 20 hours in immunospot plates coated with a monoclonal
antibody to IFN-g (TB-SPOT TB, Oxford Immunotech, Oxford, UK). IFN-g
spots were enumerated by using TB Scan software (Immunoscan, CTL-
Europe, Bonn, Germany).
Statistical Analysis
Where appropriate, comparisons were made using the Mann-Whitney
U-test or the Kruskal-Wallis test with Dunn post-test evaluation and the
Wilcoxon signed rank test for pairwise comparisons. Correlations were
based on Spearman’s r. Multivariate analysis (general linear model analysis)
was used for association between multiple variables.bility of their CB Tcells after Four Days in Complete CultureMediumwithout
rrelation with CB T Cell Viability*
earman’s r P Value by P Value
22 NS NS
76 .031 .471 .023
NS NS
54 NS NS
97 .027 .609 .005
35 NS NS
9 NS NS
medium without addition of exogenous cytokines, and viable cells (DiOC6
a signiﬁcance of P < .05 are shown.
.
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Wide Interdonor Variations in CB T Cell Viability in
Unstimulated Cultures
More than 98% of freshly collected or cryopreserved/
thawed CB T cells were viable (DiOC6(3)-positive and pro-
pidium iodide-negative) before culture. As expected, freshly
collected CB T cells left unstimulated lost their viability very
quickly after incubation in culture medium supplemented
with 10% human AB serum but devoid of exogenous
cytokines, in contrast with the marginal decrease of viable
adult blood Tcell numbers over 1 week of culture in the same
conditions. There was, however, substantial variability
among CB specimens in the proportion of cells still alive after
4 days of culture (17.4% to 79.7%) (Figure 1A). A similar or
slightly accentuated loss of viability in culture was observed
when cryopreserved/thawed CB T cells were compared to
freshly isolated CB Tcells. Variations in T cell viability were as
wide after freeze, thaw, and 4 days of culture as with fresh
cells from the same CD donor (r ¼ .785, P < .001).
Among the set of CB donor characteristics listed in Table 1,
only 2 signiﬁcant correlations with the viability of T cells
measured at day 4 were shown: a negative correlation to
infant birth weight (r ¼ .376; P ¼ .031) and a positive cor-
relation to venous CB pH (r ¼ .397; P ¼ .027). Both associa-
tions were conﬁrmed by multivariate analysis (P ¼ .023 and
P¼ .005, respectively). IL-7 is a major factor for T cell survival.
Its circulating levels are elevated in lymphopenic patients,
and, conversely, impaired viability of CB T cells might reﬂect
low in vivo exposure to the cytokine. IL-7 levels were,
therefore, measured in CB to investigate whether the
variability in CB T cell survival was associated to corre-
sponding variability in CB IL-7 levels. Although the range of
IL-7 levels in CB plasma was broad (0 to 6.67 pg/mL)
(Table 1), there was no statistically signiﬁcant correlation
with resting CB T cell viability, and the range of IL-7 levels is
as broad as in adults [13,14].
Daily Supplementation with a Low Concentration of IL-7
Can Sustain Survival of Cryopreserved/Thawed CB T Cells
In these preliminary experiments, CB T cells were main-
tained in classic culture medium containing 10% normalFigure 1. Loss of cord blood (CB) T cell viability in unstimulated cultures. Recovery of
percentage of the number of cells seeded. (A) Difference in cell viability between T cell
cultures (6 adult donors, 15 CB) were run in parallel for periods ranging between 1 a
75th percentiles (box), and whiskers (within 1.5 times the interquartile range). (B) C
viability of cryopreserved/thawed T cells from the same CB donor (21 term healthy dhuman serum, thus with one-tenth as much IL-7 as in
peripheral blood. Unstimulated T cell cultures were, there-
fore, established under the same conditions except for the
addition of recombinant human IL-7. Because cryopreserved
umbilical CB cells are commonly used for transplantation, all
of our experiments were run with cryopreserved/thawed CB
T cells. As expected, when recombinant IL-7 was added only
once at the time of seeding, more viable CB T cells were
recovered over the ﬁrst days thanwithout cytokine addition,
but the protective effect was short lived, and by 4 to 5 days
viable T cell recovery was almost as low as in cultures initi-
ated without IL-7. This transient effect is presumably attrib-
utable to consumption and/or degradation of IL-7, because its
concentration measured over sequential time points in the
cell culture supernatants was found to decrease to unde-
tectable levels over 5 days (data not shown).
The effect of daily IL-7 replenishment was, therefore,
investigated. Cryopreserved/thawed CB T cells were split and
cultured in parallel with or without daily addition of IL-7. A
proportionate increase in the viability of the resulting pop-
ulation was obtained, reaching a plateau with most cells still
alive after 7 days of culture fed daily IL-7 at 100 pg/mL
(Figure 2A). The number of viable CB T cells after 7 days of
daily IL-7 supplementation was correlated with concomitant
high level of IL-7 receptor alpha chain expression, as deter-
mined by mean ﬂuorescence intensities in ﬂow cytometric
analyses at this time point (r ¼ .93; P ¼ .0002) (data not
shown).
The proportion of the original CB T cells that went on to
divide was of limited amplitude, as less than 20% of the
resulting population was cycling and had undergone only 1
cycle of division over the 7 days of culture with 100 pg/mL of
IL-7 added daily (Figure 2B). With greater IL-7 concentra-
tions (250 pg/mL daily), more CB T cells were actively cycling
and many had undergone several cycles of division, albeit
without furthering overall cell viability (Figure 2B).
The proportions of viable cells recovered remained
equally distributed over the CD4þ and the CD8þ subsets so
that the CD4/CD8 ratio was fairly constant over the 7 days
across the range of IL-7 concentrations tested (data not
shown). RTEs were identiﬁed among CD4þ T cells by way ofviable cells (DiOC6 (3)-positive and propidium iodideenegative) is plotted as a
s freshly isolated from adult blood (upper panel) and from CB (lower panel). All
nd 7 days, as indicated. Data are presented as medians (central bar), 25th and
ell viability after 4 days of culture of freshly collected CB T cells compared to
onors).
Figure 2. Exogenously supplied recombinant human interleukin-7 (IL-7) sustains cryopreserved/thawed cord blood (CB) T cell survival. (A) Absolute counts of viable
cells (DiOC6(3)-positive and propidium iodideenegative) from 17 CB donors, seeded at 1  105 T cells/well and cultured for 7 days with or without daily supple-
mentation of IL-7 at the indicated concentration. Data are presented as box and whisker plots as described in Figure 1. Signiﬁcant differences are indicated by as-
terisks; *P < .05. (B) Flow cytometric analysis of CB T cell proliferation after 7 days of culture of CFSE-labeled T cells supplemented daily with IL-7 at 25 pg/mL, 50 pg/
mL, 100 pg/mL, 250 pg/mL, and 1000 pg/mL as indicated. Representative result of 1 of 17 experiments.
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There was no signiﬁcant difference in the relative propor-
tion of CD31þ PTK7þ CD4þ T cells cultured for 7 days with
or without daily IL-7 addition (data not shown).
Limited Alloreactivity of Cord Blood T Cells in Culture
with Daily IL-7 Supplementation
To assess whether low concentrations of IL-7 could in-
ﬂuence T cell allo-immune responses, cryopreserved/thawed
CB T cells were cocultured with HLA-mismatched stimulator
cells from adult donors. Globally, thymidine incorporation
was changed marginally if IL-7 was fed daily at 50 or 100 pg/
mL, compared with paired 1-way MLRs run without IL-7
supplementation (Figure 3A). Consistent with this limited,
if any, effect on the proliferative alloresponse, no more
interferon-g producing cells were induced with daily IL-7
supplementation than without it (Figure 3B). A modest butFigure 3. Limited potentiation of cord blood (CB) T cell alloreactivity by daily su
lymphocyte reactions (MLRs) were set up in triplicate with cryopreserved/thawed CB
out of 6 HLA mismatches, including at least 1 HLA-DR disparity). Due to the limited nu
responder cells could be run in parallel with and without only 1 concentration of IL-
incorporation at the end of 5 day MLRs. Data are presented as box and whisker plots a
harvested at the end of 1-way MLR cultures. The results are expressed as number of sp
or with IL-7 supplied daily at 100 pg/mL. NS indicates not signiﬁcant.statistically signiﬁcant increase in the absolute number of
viable lymphocytes recovered at the end of MLRs fed IL-7
daily over that without the cytokine was shown, however
(median change, þ58%; P ¼ .0001) (Figure 3C).
To get further insight, alloantigen-induced responses
were measured in ﬂow cytometry-based MLR assays.
Gating separately upon small lymphocytes and lympho-
blasts combined with CFSE dilution proﬁles indicated that
daily IL-7 supplementation improved signiﬁcantly the
recovery of viable noncycling cells (P ¼ .007), while the
numbers of cells that had undergone 1 or several cellular
divisions or cell enlargement was not signiﬁcantly
increased (Figure 4).
DISCUSSION
Unlike mature T cells from conventional allografts, CB T
cells are characterized by a rapid rate of cell death in culture,pplementation of recombinant human interleukin-7 (IL-7). One-way mixed
T cells (1  105 cells/well) and allogeneic stimulators from adult donors (4 to 6
mber of CB T cells, MLR cultures using the same combination of stimulator and
7 (7 MLRs with IL-7 at 50 pg/mL and 9 MLRs at 100 pg/mL). (A) 3H-thymidine
s in Figure 1. (B) Interferon-g ELISPOT performed with 2  105 viable CB T cells
ots from MLRs initiated with CB T cells from 11 donors, run for 5 days without
Figure 4. Daily addition of recombinant human interleukin-7 (IL-7) (100 pg/mL) sustains the survival of noncycling cord blood (CB) T cells without potentiating the
alloresponse in 1-way mixed lymphocyte reactions (MLRs). Cryopreserved/thawed CFSE-labeled CB T cells (1  105 cells/well) were cocultured with allogeneic
stimulators from adult donors (4 to 6 out of 6 HLA mismatches with at least 1 HLA-DR disparity), with or without IL-7 fed daily at 100 pg/mL. (A) Gating strategy used
to deﬁne the responder and the nonresponder CB T cells. Left panel: forward and side scatter characteristics of cells harvested after 7 days of MLR culture with IL-7.
The R1 gate was set to include small lymphocytes while excluding dead cells and debris and the R2 gate to include cells with a larger forward/side scatter proﬁle
(lymphoblasts). Right panel: ﬂuorescence intensity of CFSE, using gating separately on the small cell window (R1) and the large cell window (R2). (B) Absolute
numbers of non-cycling (small lymphocytes with undiluted CFSE dye) and of cycling cells (all cells with diluted CFSE dye and large lymphocytes with still undiluted
CFSE dye) recovered after 7 days of MLRs initiated with T cells from 13 different CB donors. Data presented as box and whisker plot as described in Figure 1. NS
indicates not signiﬁcant.
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immune reconstitution after transplantation. In this study,
we show that the viability of resting T cells is highly variable
among CB specimens and that CB T cell viability can be
maintained by a low supplemental concentration of recom-
binant human IL-7 without boosting the allo-immune
response.
All of the 34 umbilical CB samples included in this study
were collected immediately after delivery of full-term in-
fants, using a process that met the standards for banking, and
only logistical constraints had pushed these specimens out of
banking. To avoid any bias, mononuclear cells were isolated
by negative immunomagnetic selection within 3 hours after
collection. Whether freshly collected or cryopreserved/
thawed, >98% of CB T cells were viable before culture, but
most of them died readily when rested in culture without
cytokine supplementation. These data extend previous
ﬁndings [4,17] to show that the proportion of resting CB T
cells undergoing apoptosis is highly variable among donors,
as one half or more CB Tcells from some specimens were still
alive on day 4, whereas almost all T cells from other donors
had died. From a practical point of view, determination of the
initial viability of CB T cells before cryopreservation cannot,
therefore, predict their resistance to apoptosis.Paradoxically, CB plasma levels of IL-7 were not signiﬁ-
cantly correlated with resting T cell survival, although some
specimens had levels under the detection threshold. How-
ever, plasma levels may not accurately reﬂect IL-7 availability
in fetal tissues, wherein the cytokine is produced by stromal
cells and utilized by peripheral T cells [5]. Among all donor
characteristics and subset composition of CB T cells, only
birth weight and CB venous pH were signiﬁcantly associated
in univariate and multivariate analyses with resting CB T cell
viability on day 4. Birth weight is known to be correlated
with perinatal and long-term outcomes [18]. Mononuclear
cell count in CB is known to be negatively correlated with CB
pH [19], which suggests that fetal hypoxic conditions may
compromise cell survival or at least exaggerate the pro-
pensity of CB T lymphocytes to undergo apoptosis. Although
a rest period in culture cannot mimic the in vivo postinfusion
conditions exactly, our results raise, therefore, some ques-
tions about banking umbilical CB from infants with low birth
weight and/or low umbilical venous pH.
Building on the well-accepted capacity of exogenous IL-7
to prevent apoptosis of naïve T cells and RTEs [8,9] but also to
lower the threshold for T cell activationwith the possible risk
of exaggerating alloreactivity [11], we evaluated the survival
of CB T cells in the presence of a range of concentrations of
L. Pascal et al. / Biol Blood Marrow Transplant 21 (2015) 625e631630recombinant human IL-7. Because we found that survival
was signiﬁcantly associated with freshly collected or cry-
opreserved/thawed T cells from the same donors, cry-
opreserved/thawed cells were tested, given that umbilical CB
units are cryopreserved for use. The best prosurvival effect
was obtained with daily supplementation with a low
concentration of IL-7 (100 pg/mL), allowing us to recover
almost as many viable T cells as set up in culture. This fairly
constant cell count over the 7 days in unstimulated cultures
can be attributed to maintenance of viability and not death
retardation by IL-7, as cell viability was monitored by stain-
ing with DiOC6(3), the uptake of which is lost at the early
stage of apoptosis.
Only a few cells (<20%) were cycling after 7 days in cul-
ture, a culture period long enough to evaluate cell-cycle
entry [4]. Conversely, more cells proliferated when higher
concentrations of IL-7 were tested, albeit with no gain of
viability. With 100 pg/mL IL-7 daily, expression of the IL-7
receptor alpha chain was preserved after 7 days of culture,
indicating that this low concentration of IL-7 had not
induced a substantial down-regulation of alpha chain
expression, and that CB T cells were keeping their capacity to
bind the cytokine. The CD4 to CD8 ratio and the relative
proportion of CD31þ PTK7þ were preserved just as well,
consistent with the fact that both RTEs and naive CD4þ and
CD8þ T cells express high levels of IL-7 receptor alpha chain.
These results suggest that a low effective dose of IL-7 has
exerted a fairly homogeneous prosurvival effect on both
immature RTEs and mature CB T cell populations, and the
results conﬁrm that most cells remained quiescent, given
that surface PTK7 expression would have been lost upon
cytokine-induced cycling [3].
Despite running 1-way MLRs with highly immunogenic
stimulators (at least 4 of 6 mismatches with at least 1
HLA-DR disparity), daily supplementationwith 100 pg/mL of
IL-7 did not lead to any signiﬁcant enhancement of the
alloreactive immune response, as evaluated both by the
proliferation rate (3H-thymidine incorporation and CFSE
dilution) and the production of interferon-g (ELISPOT).
However, slightly more lymphocytes were viable at the end
of 1-way MLRs fed IL-7 than without the cytokine. Compar-
ison of absolute cell counts and CFSE dilution proﬁles by
gating separately allowed attributing this increase to the
survival of a greater number of small undivided lymphocytes,
in line with the prosurvival effect of IL-7 discussed above,
while the number of enlarged or already divided cells was
not signiﬁcantly different between MLRs run with and
without IL-7.
Altogether, these data indicate that daily supplementa-
tion with a low dose of IL-7 can promote CB T cell survival
much more than cell-cycle entry and expansion. Neonatal T
cells are known to be highly sensitive to IL-7 [3,12].
Maintenance of T cell quiescence by a low dose of IL-7 is
consistent with reports showing that the signaling
threshold for the prosurvival effect of IL-7 is lower than for
continuous down-regulation of IL-7 receptor alpha chain
expression, cell-cycle entry, and proliferative expansion
[17]. Others have reported that IL-7 feeding to sustain CB T
cell survival was required only at the time of seeding [17];
however, their experiments were run in fetal calf serum, a
better supportive supplementation for human T cell cul-
tures than pooled human AB sera [20], but which is of
course not physiologically found in humans. Daily supple-
mentation may be required because the cytokine is
consumed and/or degraded rapidly in the culture, so thatdaily feeding will led to peak and trough levels, in accor-
dance with the fact that intermittent IL-7 signaling, as it is
experienced in vivo, maintains the quiescence and survival
of naïve T cells [21]. This effective concentration is 1 or 2
logs lower than the peak levels obtained after pharmaco-
logical administration of the cytokine in clinical trials [6,7]
and somewhat higher than peak levels of endogenous IL-7
in the peripheral circulation after myeloablative condi-
tioning [5,10,12,21,22], but as mentioned above, circulating
levels do not accurately estimate IL-7 availability in tissular
sites. In fact, the effective concentration of IL-7 found to
keep CB T alive in our study is equivalent to the upper
estimate of in vivo homeostatic IL-7 tissular concentrations
in lymphoreplete mice [23], thus, in physiological condi-
tions where the vast majority of naïve T cells remains
quiescent.
Recombinant human IL-7 has recently been tested in the
allogeneic hematopoietic stem cell transplantation setting,
showing an encouraging improvement in T cell recovery
without increased incidence of high grade acute GVHD at the
high plasma IL-7 concentration obtained (nanogram/mL
range) [7]. Because T celledepleted allografts were given in
this trial, the risk of boosting alloreactivity by a course of IL-7
after unmanipulated allografts cannot be ruled out. From a
clinical immunotherapy perspective, preserving the survival
of infused T cell is particularly desirable after umbilical CB
transplantation. Even though in vitro cultures cannot provide
perfect replicas of in vivo processes, our data suggest that
administration of lower doses of recombinant human IL-7
than used in previous trials may be sufﬁcient to sustain the
viability of infused CB T cells without potentiating their
alloreactivity, and thus help to accelerate naïve T cell
reconstitution while minimizing the potential adverse
effects of allo-immune responses.ACKNOWLEDGMENTS
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